ICON Launches New Patient Engagement Platform to Support Improved Patient Experience and Enrollment in Clinical Trials
2019年5月9日 - 8:00PM
ビジネスワイヤ(英語)
Increasing visibility of potential study
participants to sites and sponsors
ICON plc, (NASDAQ: ICLR) a global provider of drug and device
development and commercialisation services to the pharmaceutical,
biotechnology and medical device industries, today announced the
release of its web based patient engagement platform, to provide
patients with study specific information and connectivity with the
nearest investigative site. The solution supplements patient
recruitment outreach by sites and increases visibility of potential
study participants for sponsors and sites.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190509005053/en/
Patient recruitment specialists work with sponsors to develop
outreach programs that incorporate the right mix of digital
channels, traditional methods and patient advocacy partnerships to
attract patients to a study branded website hosted on the platform.
An easy to navigate, user friendly interface guides the patient to
new and ongoing studies in their particular indication and a
pre-qualification questionnaire helps to determine if the study is
a right fit for them. If the patient decides to register interest,
they are given the option to select their nearest investigative
site. This establishes connection with the site and the patient can
then choose to contact the site or ask to be contacted for
pre-screening.
By being able to access the mobile optimised website at home,
patients are able to discuss the possibility of trial participation
as a clinical care option with their family and caregivers. Making
it easier for the patient to register interest will increase access
to potential patients for sponsors. The platform will also enable
site staff to see the number of pre-qualification questionnaires
completed in near real-time to monitor and report on progress to
sponsors.
“Access to patients continues to be the biggest challenge for
sponsors, impacting speed to market and overall drug development
costs,” commented EB McLindon, Senior VP Site & Patient
Solutions, “We have used our understanding of patients gained
through managing thousands of trials to develop this patient
engagement platform and ease the burden on sites and patients. This
will increase the predictability and speed of patient
recruitment”.
About ICON plc
ICON plc is a global provider of outsourced drug and device
development and commercialisation services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. The company specialises in the strategic
development, management and analysis of programs that support
clinical development - from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
employed approximately 13,920 employees in 90 locations in 37
countries as at March 31, 2019. Further information is available at
www.iconplc.com/patient-platform
ICON/ICLR-G
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190509005053/en/
ICON Media:Lucinda Sandon-AllumWeber Shandwick+44
(0)2070670548lsandon-allum@webershandwick.com
ICON (NASDAQ:ICLR)
過去 株価チャート
から 6 2024 まで 7 2024
ICON (NASDAQ:ICLR)
過去 株価チャート
から 7 2023 まで 7 2024